POPEK: Platform for Onco-PharmacoEPidemiology and Kinetic for a better understanding of anticancer drug use, safety and effectiveness in real life practice

  • Clinical research
  • Datamining/Epidemiology
  • In-vivo pharmacology
ISO:27001
Localization
CHU Pellegrin
DEMANDE D'UTILISATION

Contact

Description

POPEK platform aims to develop new research activities in close collaboration with oncologist and geriatricians. We try to better understand the patterns of use and effects (beneficial and adverse) of anticancer drugs in real-life practice: how they compare with what have been reported in clinical trials and how they are used and effective and safe in specific populations such as elderly patients. Our analysis will also allow a better monitoring of patient presenting with cancer disease to optimize benefit and minimize risks.

Activity

  1. Surveillance of Adverse Drug Reaction: signal detection and investigation based on spontaneous reporting databases, active surveillance in cohort studies, or Health Insurance Databases. Data mining techniques.
  2. Design and conduction of pharmacoepidemiologic studies (drug use patterns, assessment of risks & benefit, assessment of benefit-risk balance). a. Based on data collected among health care personnel and/or patient’s medical files. b. Based on data contained in the French Health Insurance databases (Echantillon Généraliste des Bénéficiaires and SNIIRAM) or other Electronic Health Care databases.
  3. Development of electronic tools to collect and electronic databases to store medical data.
  4. Use of propensity scores and disease risk scores to adjust for confounding factors in observational studies
  5. Monitoring and optimization of cancer drugs use, determination of concentration thresholds predictive of anticancer targeted therapies clinical response.

Publication

  1. Rouyer M, Smith D, Laurent C, Becouarn Y, Guimbaud R, Michel P, Tubiana-Mathieu N, Balestra A, Jové J, Robinson P, Noize P, Moore N, Ravaud A, Fourrier-réglat A. Secondary metastases resection after bevacizumab plus irinotecan-based chemotherapy in first-line therapy of metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. Target Oncol (in press)
  2. Fourrier-Réglat A, Noize P, Facon T, Fermand JP, Fitoussi O, Marit G, Thomaré P, Robinson E, Jové J, Lassalle R, Rouyer M, Grelaud A, Moore N and the Vesuve group. Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study. Leukemia and lymphoma 2014; 55: 848-54
  3. Fourrier-Réglat A, Smith D, Rouyer M, Bénichou J, Gimbaud R, Bécouarn Y, Bernard O, Noize P, Moore N, Ravaud A. Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. Targeted Oncology 2014; 9: 311-9
  4. Smith D, Terrebonne E, Rouyer M, Blanc JF, Breilh D, Pedeboscq S, Le Monies A, Lecomte C, Lassalle R, Moore N, Fourrier-Réglat A. Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study. Fundam Clin Pharmacol 2013; 27: 113-9
  5. Bernard MA, Bénichou J, Blin P, Weill A, Bégaud B, Abouelfath A, Moore N, Fourrier-Réglat A; on behalf of the CADEUS team. Use of health insurance claim patterns to identify patients using nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Pharmacoepidemiol Drug Saf 2012; 21: 573-83

Collaboration

Design and conduction of cohort studies with oncologists at the national level in various cancers and with cancer networks (Réseau de cancérologie Aquitain, réseau d’oncologie midi-pyrénées). Development of the UroCCR clinico-biological database. Member of European consortium for the conduction of FP7 projects (Eu-ADR, SOS, Aritmo). Leader of an IMI-JU funded training programme in Pharmacovigilance & Pharmacoepidemiology. Leader of the DRUGS-SAFE platform funded by the French Medicine Agency (ANSM).